Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062114 · ClinicalTrials.gov registry record · Phase 2
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT00062114 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 84 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00062114, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with progressive non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL rituximab
- RADIATION yttrium Y 90 ibritumomab tiuxetan
Study Locations (20)
Illinois
- Rush-Copley Cancer Care Center - Aurora
- University of Illinois Cancer Center - Chicago
- University of Chicago Cancer Research Center - Chicago
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- Carle Cancer Center at Carle Foundation Hospital - Urbana
- CCOP - Carle Cancer Center - Urbana
California
- Providence Saint Joseph Medical Center - Burbank - Burbank
- Moores UCSD Cancer Center - La Jolla
- Kaiser Permanente Medical Office -Vandever Medical Office - San Diego
Indiana
- St. Francis Hospital and Health Centers - Beech Grove Campus - Beech Grove
- Saint Anthony Memorial Health Centers - Michigan City
- Reid Hospital & Health Care Services, Incorporated - Richmond
Kansas
- Tammy Walker Cancer Center at Salina Regional Health Center - Salina
- Cotton-O'Neil Cancer Center - Topeka
- St. Francis Comprehensive Cancer Center - Topeka
Delaware
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Maine
- Central Maine Comprehensive Cancer Center at Central Maine Medical Center - Lewiston
Maryland
- Union Hospital Cancer Program at Union Hospital - Elkton MD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062114
The ClinicalTrials.gov registry entry for NCT00062114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which rituximab is the first listed.
NCT00062114 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Illinois, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT00062114 about?
NCT00062114 is a clinical study titled "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well giving yttrium Y 90 ibritumo...
What is the current status of trial NCT00062114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2004-04. Estimated completion is 2007-04.
What conditions does trial NCT00062114 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00062114?
The interventions under investigation include: rituximab (BIOLOGICAL), yttrium Y 90 ibritumomab tiuxetan (RADIATION).
Who is sponsoring clinical trial NCT00062114?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00062114 being conducted?
This trial has 20 study locations across Arkansas, California, Delaware, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.